Profile data is unavailable for this security.
About the company
Cogstate Limited is a neuroscience technology company optimizing brain health assessments to advance the development of new medicines and to enable earlier clinical insights in healthcare. Its principal activities are the creation, validation, and commercialization of digital brain health assessments; and design and provision of quality assurance services in clinical trials, focused on the administration, scoring, and recording of conventional brain health assessments. Its segments include Clinical Trials, Healthcare, and Administration. In the Clinical Trials segment, the technology and associated services are used to quantify the effect of disease and of drugs, devices or other interventions on human subjects participating in clinical trials primarily conducted by pharmaceutical, and biotechnology companies. In the Healthcare segment, the technology and associated services are being developed as a tool for primary care physicians and/or hospitals to assess cognitive decline.
- Revenue in AUD (TTM)64.21m
- Net income in AUD8.06m
- Incorporated1999
- Employees61.00
- LocationCogState LtdLevel 2, 161 Collins StreetMELBOURNE 3000AustraliaAUS
- Phone+61 39664-1300
- Fax+61 39664-1301
- Websitehttps://cogstate.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Proteomics International LaboratoriesLtd | 1.41m | -6.38m | 85.15m | -- | -- | 9.04 | -- | 60.41 | -0.0507 | -0.0507 | 0.0112 | 0.0719 | 0.1346 | -- | 6.45 | -- | -61.88 | -60.46 | -67.65 | -69.49 | -- | -- | -459.82 | -290.18 | -- | -208.63 | 0.0331 | -- | -4.24 | -1.45 | -3.23 | -- | 60.39 | -- |
| Percheron Therapeutics Ltd | 615.48k | -11.92m | 88.35m | 8.00 | -- | 9.44 | -- | 143.55 | -0.0135 | -0.0135 | 0.0007 | 0.0104 | 0.045 | -- | 0.2912 | -- | -87.09 | -75.92 | -122.82 | -89.91 | -- | -- | -1,936.57 | -4,028.81 | -- | -1,956.65 | 0.0042 | -- | 59.90 | 56.21 | -4.74 | -- | -- | -- |
| Argenica Therapeutics Ltd | 192.09k | -5.48m | 100.44m | -- | -- | 7.00 | -- | 522.85 | -0.0518 | -0.0518 | 0.0019 | 0.1128 | 0.0148 | -- | 0.7326 | -- | -42.28 | -- | -50.70 | -- | -- | -- | -2,852.56 | -- | -- | -21,829.87 | 0.00 | -- | 214.90 | -- | -13.80 | -- | -- | -- |
| LTR Pharma Ltd | 49.00k | -6.95m | 150.08m | -- | -- | 83.92 | -- | 3,062.79 | -0.0499 | -0.0499 | 0.0004 | 0.0211 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -14,192.84 | -- | -- | -414.02 | 0.00 | -- | -- | -- | -378.00 | -- | -- | -- |
| Cogstate Ltd | 64.21m | 8.06m | 168.28m | 61.00 | 20.90 | 2.75 | 13.90 | 2.62 | 0.0467 | 0.0467 | 0.371 | 0.3543 | 0.7762 | -- | 4.96 | -- | 9.74 | 8.45 | 12.51 | 12.30 | 55.96 | 53.13 | 12.55 | 10.75 | -- | -- | 0.0162 | 0.00 | 7.36 | 14.72 | 52.75 | -- | -5.00 | -- |
| Arovella Therapeutics Ltd | 155.73k | -8.75m | 168.28m | 14.00 | -- | 14.97 | -- | 1,080.62 | -0.0093 | -0.0093 | 0.0002 | 0.0107 | 0.0166 | -- | 30.42 | -- | -93.26 | -78.61 | -116.36 | -96.29 | 100.00 | 51.81 | -5,616.16 | -2,126.97 | -- | -1,012.45 | 0.00 | -- | -64.27 | -34.07 | 14.10 | -- | -37.76 | -- |
| Dimerix Ltd | 583.48k | -17.08m | 211.67m | 0.00 | -- | 11.50 | -- | 362.77 | -0.0373 | -0.0373 | 0.0013 | 0.0331 | 0.0234 | -- | 0.0612 | -- | -68.53 | -71.97 | -98.37 | -113.16 | -- | -- | -2,926.42 | -8,332.83 | -- | -- | 0.0082 | -- | 1,485.97 | 100.27 | -23.71 | -- | 17.99 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Australian Ethical Investments Ltd. (Investment Management)as of 30 Jun 2024 | 16.53m | 9.68% |
| FIL Investment Management (Hong Kong) Ltd.as of 31 Jul 2024 | 5.04m | 2.95% |
| Fidelity Management & Research (Hong Kong) Ltd.as of 31 Jul 2024 | 1.94m | 1.14% |
| Mutual Trust Pty Ltd.as of 30 Jun 2024 | 1.13m | 0.66% |
| Dimensional Fund Advisors LPas of 05 Sep 2024 | 752.23k | 0.44% |
| DFA Australia Ltd.as of 31 Jul 2024 | 682.86k | 0.40% |
| Mandarine Gestion SAas of 29 Feb 2024 | 45.00k | 0.03% |
| Dimensional Fund Advisors Ltd.as of 05 Sep 2024 | 13.69k | 0.01% |
| Acadian Asset Management LLCas of 31 Dec 2023 | 7.42k | 0.00% |
